The Division of Gynecologic Oncology has one of the largest Clinical Trial Research Programs in Northern California and is on the forefront of translational research in gynecologic cancers. Through the collaborative work of our providers, research team and other UCSF staff, we offer a wide variety of clinical trials that provide women with gynecologic cancers access to cutting edge investigational therapies and treatment methods. Our practice serves as a regional research hub which attracts patients from across California seeking out clinical trials. Additionally, we are a voting member of the national Cooperative Group NRG Oncology, an interdisciplinary research organization dedicated to improving the survival and quality of life of cancer patients through research, where we help to shape Gynecologic Oncology care on a national and global level. We are excited to continue to grow our Clinical Research Program by adding additional staff and expanding our trial portfolio, with the goal of being able to provide any woman with gynecologic cancer interested in participating in a clinical trial access to potentially life-saving therapy.
GARNET A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors NCT02715284 PI: Lee-may Chen, MD
ARIEL4: A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer is now open to accrual NCT02855944 PI: Lee-may Chen, MD
ADXS001-04 (Estimated open Summer 2018) PHASE 1-2 Study of MEDI4736 alone or in combination with ADXS11-001 in recurrent/persistent or metastatic cervical cancer NCT02291055 PI: Stefanie Ueda, MD
ABI1968-102 (Estimated open Fall 2018) A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects with Cervical High Grade Squamous Intraepithelial Lesions (cHSIL) NCT0323922 PI: Karen Smith-McCune
MK3475-775 (Estimated open Fall 2018) A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with Advanced Endometrial Cancer PI: Edwin Alvarez, MD
Cooperative Group Trials
NRG-GY008 (Currently on hold) A Phase II Evaluation of COPANLISIB (BAY 80-6946) (IND #130822), a selective inhibitor of PI3KCA, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutation NCT02728258 PI: Edwin Alvarez, MD
NRG-GY005 (Currently on hold) A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) NCT02502266 PI: Jocelyn Chapman, MD
GOG-3015 A Phase III, Multi-center, Randomized Study of Atezolizumab versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly Diagnosed Stage III or State IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT03038100 PI: Lee-may Chen, MD
GOG-3009 A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV NCT02853604 PI: Stefanie Ueda, MD
If you would like more information regarding our Gynecologic Oncology Trials at UCSF, please email our team at GynOncClinicalTrials@UCSF.edu.
For the most recent list of clinical trials, please visit: https://clinicaltrials.ucsf.edu.